Literature DB >> 15025835

Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.

Mohamed Omar Tawfik1, Vladimir Bryuzgin, Galina Kourteva.   

Abstract

OBJECTIVE: To determine the safety and efficacy of transdermal fentanyl for pain relief in cancer patients and to compare the effects on patients according to whether they had previously received strong opioids, weak opioids or non-opioid analgesia.
METHODS: Cancer patients requiring strong analgesia were recruited into an open-label, multicentre study, conducted in eight countries. Patients received transdermal fentanyl treatment for 28 days. Pain severity, overall satisfaction with pain control, convenience of use of patches and treatment preferences were recorded daily.
RESULTS: Of the 292 participants, 135 had previously received a strong opioid, 84 had previously received a weak opioid and 73 had received no regular opioids. Thirty-eight patients did not complete the study, mainly due to adverse events. For all groups the proportion of patients with 'good to excellent' pain control increased after transdermal fentanyl treatment. Transdermal fentanyl was well tolerated, with the most common treatment-related adverse events being nausea, vomiting and constipation. The percentage of strong-opioid-tolerant patients with constipation decreased following transdermal fentanyl treatment and increased slightly in the strong-opioid-naïve groups. Most patients rated the convenience of the patches as 'good to excellent', and most preferred transdermal fentanyl to their previous therapy.
CONCLUSIONS: Transdermal fentanyl is an effective and well-tolerated treatment for cancer-related pain for patients regardless of whether they have previously received opioids. Previous guidelines have often advocated initial dose finding with short-acting opioids but this study demonstrates that such a complex titration and conversion schedule may not be necessary,and that treatment may be initiated directly with long-acting formulations such as transdermal fentanyl when previous analgesic therapy fails to provide adequate relief.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15025835     DOI: 10.1185/030079903125003026

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  9 in total

Review 1.  [Diagnosis and therapy of tumor related pain].

Authors:  M Kloke
Journal:  Urologe A       Date:  2007-01       Impact factor: 0.639

2.  [Prophylactic measures and acute treatment of migraine].

Authors:  H Göbel; A Heinze; K Heinze-Kuhn
Journal:  Schmerz       Date:  2006-11       Impact factor: 1.107

3.  Adverse events of opioids for cancer-related pain in a resource-limited setting: a cross-sectional study from Sudan.

Authors:  Moawia Mohammed Ali Elhassan; Amal Abdulbagi Abdulfatah Mohammed; Amnah Abdulazeem Omer; Arafa Ahmed Mohammed Azeem; Hiba Mohammed Abdelkfi Mohammed; Isra Elameen Mustafa Ibrahim; Nashwa Abdelaziz Abdelrheem Ahmed
Journal:  Ecancermedicalscience       Date:  2022-03-24

4.  Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.

Authors:  Carla Ripamonti; Elena Fagnoni; Tiziana Campa; Cinzia Brunelli; Franco De Conno
Journal:  Support Care Cancer       Date:  2006-02-17       Impact factor: 3.603

Review 5.  Transdermal fentanyl: pharmacology and toxicology.

Authors:  Lewis Nelson; Robert Schwaner
Journal:  J Med Toxicol       Date:  2009-12

6.  Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.

Authors:  Barbara Silvestri; Elena Bandieri; Salvatore Del Prete; Giovanni Pietro Ianniello; Giuseppe Micheletto; Mario Dambrosio; Giovanni Sabbatini; Luigi Endrizzi; Alessandro Marra; Enrico Aitini; Angioletta Calorio; Ferdinando Garetto; Giuseppe Nastasi; Francovito Piantedosi; Vincenzo Sidoti; Piergiorgio Spanu
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

7.  Opioid rotation versus combination for cancer patients with chronic uncontrolled pain: a randomized study.

Authors:  Hyun-Jun Kim; Young Saing Kim; Se Hoon Park
Journal:  BMC Palliat Care       Date:  2015-09-16       Impact factor: 3.234

8.  The use of rotation to fentanyl in cancer-related pain.

Authors:  Delia Dima; Ciprian Tomuleasa; Ioana Frinc; Sergiu Pasca; Lorand Magdo; Ioana Berindan-Neagoe; Mihai Muresan; Cosmin Lisencu; Alexandru Irimie; Mihnea Zdrenghea
Journal:  J Pain Res       Date:  2017-02-09       Impact factor: 3.133

9.  Transdermal fentanyl for pain due to chemoradiotherapy-induced oral mucositis in nasopharyngeal cancer patients: evaluating efficacy, safety, and improvement in quality of life.

Authors:  Su-Ping Guo; San-Gang Wu; Juan Zhou; Hui-Xia Feng; Feng-Yan Li; Ying-Jia Wu; Jia-Yuan Sun; Zhen-Yu He
Journal:  Drug Des Devel Ther       Date:  2014-05-12       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.